Search Results
Feb 02, 2026, 08:00 ET BANQUET® MEGA™ BREAKFAST BOWLS DELIVER BIG PROTEIN FOR YOUR MORNING
BowlCHICAGO, Feb. 2, 2026 /PRNewswire/ -- Conagra Brands, Inc. (NYSE: CAG), one of North America's leading branded food companies, is bringing a protein-packed new offering to breakfast with the debut of new Banquet®
More news about: Conagra Brands, Inc.
Jan 29, 2026, 08:05 ET Skyhawk Therapeutics 公佈其用於治療 Huntington 疾病的藥物 SKY-0515 於第 1 期臨床試驗中 受試患者的九個月中期結果。
SKY-0515 可使血液中的 mHTT 蛋白呈現劑量依賴性降低，在 9 毫克劑量下減幅達 62%，同時 PMS1 mRNA 劑量依賴性降低 26%。 PMS1 是體細胞 CAG 重複序列擴張和 HD 病理的關鍵驅動因素。 SKY-0515 亦表現出優異的中樞神經系統藥物暴露度，整體上安全且耐受性良好。在 SKY-0515 第 1 期臨床試驗 C 部分患者群組中，接受 SKY-0515 治療的患者在 3 個月、6 個月和 9 個月時，其綜合統一 Huntington
More news about: Skyhawk Therapeutics
Jan 29, 2026, 07:48 ET A Skyhawk Therapeutics anuncia resultados provisórios de nove meses em pacientes de seu ensaio clínico de fase 1 do SKY-0515 como tratamento para a doença de Huntington
sangue de 62% com a dose de 9 mg e uma redução da dose dependente do mRNA PMS1 de 26%. O PMS1 é um fator determinante da expansão da repetição somática CAG e da patologia da DH. O SKY-0515 também demonstrou excelente exposição ao sistema nervoso central e foi geralmente seguro e bem tolerado.Aos três,
More news about: Skyhawk Therapeutics
Jan 29, 2026, 07:46 ET Skyhawk Therapeutics anuncia resultados provisionales de nueve meses en pacientes de su ensayo clínico de fase 1 de SKY-0515 como tratamiento para la enfermedad de Huntington
reducción dependiente de la dosis del ARNm de PMS1 del 26 %. El PMS1 es un factor clave de la ampliación de la repetición de la citosina-adenina-guanina (CAG) somático y la patología de la enfermedad de Huntington. SKY-0515 también ha demostrado una excelente exposición al sistema nervioso central y ha sido
More news about: Skyhawk Therapeutics
Jan 28, 2026, 12:57 ET Skyhawk Therapeutics gibt Neun-Monats-Zwischenergebnisse bei Patienten aus der klinischen Phase-1-Studie mit SKY-0515 zur Behandlung der Huntington-Krankheit bekannt
Blut um 62 % bei einer Dosis von 9 mg und zu einer dosisabhängigen Verringerung der PMS1-mRNA um 26 %. PMS1 ist ein Schlüsselfaktor für die somatische CAG-Repeat-Expansion und die HD-Pathologie. SKY-0515 hat ebenfalls eine hervorragende Exposition des Zentralnervensystems gezeigt und ist im Allgemeinen
More news about: Skyhawk Therapeutics
Jan 28, 2026, 12:09 ET Skyhawk Therapeutics Umumkan Hasil Sementara Uji Klinis SKY-0515 Tahap 1 Selama Sembilan Bulan Pada Pasien Sebagai Pengobatan Penyakit Huntington
darah sebesar 62% pada dosis 9 mg, dan penurunan mRNA PMS1 sebesar 26% yang bergantung pada dosis. PMS1 adalah pendorong utama ekspansi pengulangan CAG somatik dan patologi HD. SKY-0515 juga telah menunjukkan paparan sistem saraf pusat yang sangat baik, secara umum aman dan dapat ditoleransi dengan baik.Pada
More news about: Skyhawk Therapeutics
Jan 28, 2026, 11:54 ET Skyhawk Therapeutics annonce les résultats intermédiaires à neuf mois de son essai clinique de Phase 1 du SKY-0515 comme traitement de la maladie de Huntington
réduction de 26 %, elle aussi proportionnelle à la dose administrée, de l'ARNm PMS1. Le PMS1 est un facteur clé de l'expansion répétée d'un trinucléotide CAG somatique et de la pathologie de la maladie de Huntington. Le SKY-0515 a également démontré une excellente exposition du système nerveux central et était
More news about: Skyhawk Therapeutics
Jan 28, 2026, 04:14 ET Компания Skyhawk Therapeutics объявляет промежуточные результаты за девять месяцев среди пациентов клинического исследования фазы 1 препарата SKY-0515 для лечения болезни Гантингтона
уровня белка mHTT в крови на 62 % при дозе 9 мг и дозозависимому снижению мРНК PMS1 на 26 %. PMS1 является ключевым фактором соматической экспансии CAG-повторов и патологии болезни Гантингтона. Препарат SKY-0515 также продемонстрировал отличное воздействие на центральную нервную систему, общую безопасность
More news about: Skyhawk Therapeutics
Jan 28, 2026, 03:11 ET Společnost Skyhawk Therapeutics oznamuje průběžné výsledky za devět měsíců u pacientů z 1. fáze klinického hodnocení přípravku SKY-0515 pro léčbu Huntingtonovy choroby
závislosti na dávce ke snížení obsahu proteinu mHTT v krvi o 62 % a k redukci mRNA PMS1 o 26 % při dávce 9 mg. PMS1 je klíčovým faktorem expanze somatických CAG repetic a patologie HD. Přípravek SKY-0515 rovněž prokázal vynikající expozici centrálního nervového systému a je obecně bezpečný a dobře se snáší.Po
More news about: Skyhawk Therapeutics
Jan 27, 2026, 22:10 ET Spoločnosť Skyhawk Therapeutics oznamuje predbežné výsledky u pacientov z fázy 1 klinického skúšania lieku SKY-0515 za deväť mesiacov liečby Huntingtonovej choroby
62 % pri dávke 9 mg a k dávkovo závislému zníženiu hladiny mRNA proteínu PMS1 o 26 %. Proteín PMS1 je kľúčovým faktorom expanzie opakovaní somatického CAG a patológie HD. Liek SKY-0515 tiež preukázal vynikajúci vplyv na centrálny nervový systém a bol vo všeobecnosti bezpečný a dobre tolerovaný.Po
More news about: Skyhawk Therapeutics
Jan 27, 2026, 10:22 ET Skyhawk Therapeutics Công Bố Kết Quả Nghiên Cứu Tạm Thời trên Bệnh Nhân sau 9 Tháng tiến hành Thử Nghiệm Lâm Sàng Giai Đoạn 1 thuốc SKY-0515 để Điều Trị bệnh Huntington
protein mHTT trong máu với liều 9mg (phụ thuộc liều) và giảm 26% lượng mRNA PMS1 (phụ thuộc liều). PMS1 là yếu tố then chốt thúc đẩy sự mở rộng lặp đoạn CAG trong tế bào soma và sự tiến triển bệnh lý của HD. SKY-0515 cũng đã chứng minh khả năng tiếp cận tuyệt vời với hệ thần kinh trung ương và nhìn chung
More news about: Skyhawk Therapeutics
Jan 27, 2026, 09:40 ET Skyhawk Therapeutics ogłasza dziewięciomiesięczne wyniki pośrednie badań klinicznych fazy 1 nad lekiem SKY-0515 stosowanym w leczeniu choroby Huntingtona
przy dawce 9 mg oraz zależne od dawki zmniejszenie stężenia mRNA PMS1 o 26%. PMS1 jest kluczowym czynnikiem powodującym somatyczną ekspansję powtórzeń CAG i patologię HD. Lek SKY-0515 wykazał również doskonałą ekspozycję w ośrodkowym układzie nerwowym i był ogólnie bezpieczny i dobrze tolerowany.Po
More news about: Skyhawk Therapeutics
Jan 27, 2026, 09:37 ET Skyhawk Therapeutics anuncia resultados de su ensayo clínico de SKY-0515 para la enfermedad de Huntington
62 % con la dosis de 9 mg, y una reducción dependiente de la dosis del ARNm de PMS1 del 26 %. PMS1 es un factor clave en la expansión de repeticiones CAG somáticas y la patología de la EH. SKY-0515 también ha demostrado una excelente exposición al sistema nervioso central y, en general, ha sido seguro
More news about: Skyhawk Therapeutics
Jan 27, 2026, 08:00 ET 스카이호크 테라퓨틱스, 헌팅턴병 치료제 SKY-0515 제1상 임상시험 환자 대상 9개월 중간 결과 발표
SKY-0515 투여 결과 9mg 용량에서 혈액 내 변이 헌팅틴 단백질(mHTT)이 62% 감소하는 등 용량 의존적 감소가 나타났으며, 체세포 CAG 반복 확장 및 헌팅턴병 병리학의 핵심 동인인 PMS1 mRNA는 26% 감소했다. 또한 SKY-0515는 우수한 중추신경계 노출을 입증했으며 전반적으로 안전하고 내약성이 우수한 것으로 나타났다.제1상 임상시험 파트 C 환자 코호트에서 SKY-0515를 투여받은
More news about: Skyhawk Therapeutics
Jan 27, 2026, 08:00 ET Skyhawk Therapeutics Announces Nine Month Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington's Disease
dose-dependent reductions of mHTT protein in blood of 62% at the 9mg dose, and dose-dependent PMS1 mRNA reduction of 26%. PMS1 is a key driver of somatic CAG repeat expansion and HD pathology. SKY-0515 has also demonstrated excellent central nervous system exposure and been generally safe and well tolerated.At
More news about: Skyhawk Therapeutics
Jan 27, 2026, 08:00 ET Skyhawk Therapeutics Announces Nine Month Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington's Disease
dose-dependent reductions of mHTT protein in blood of 62% at the 9mg dose, and dose-dependent PMS1 mRNA reduction of 26%. PMS1 is a key driver of somatic CAG repeat expansion and HD pathology. SKY-0515 has also demonstrated excellent central nervous system exposure and been generally safe and well tolerated.At
More news about: Skyhawk Therapeutics
Jan 14, 2026, 07:30 ET Conagra Brands' Future of Frozen Food 2026 Reviews Trends Shaping $93.5 Billion Industry
Conagra Brands' Future of Frozen Food 2026 ReportAbout Conagra BrandsConagra Brands, Inc. (NYSE: CAG), is one of North America's leading branded food companies. We combine a 100-year history of making quality food with agility and a relentless focus on
More news about: Conagra Brands, Inc.
Dec 19, 2025, 07:30 ET CONAGRA BRANDS REPORTS SECOND QUARTER RESULTS
CHICAGO, Dec. 19, 2025 /PRNewswire/ -- Today Conagra Brands, Inc. (NYSE: CAG) reported results for the second quarter of fiscal year 2026, which ended on November 23, 2025. All comparisons are against the prior year fiscal period,
More news about: Conagra Brands, Inc.
Dec 18, 2025, 07:30 ET Conagra Brands Announces Quarterly Dividend Payment
Dec. 18, 2025 /PRNewswire/ -- Conagra Brands, Inc. (NYSE: CAG) today announced that its Board of Directors approved a quarterly dividend payment of $0.35 per share of CAG common stock to be paid on February 26, 2026 to stockholders of record as of the close of business
More news about: Conagra Brands, Inc.
Dec 03, 2025, 08:30 ET MHK Introduces SmartProminence®--Natively Built AI-Powered Solutions that Drive Operational Excellence
suite. Featuring AI-powered capabilities across MHK's platform, with initial focus on Utilization Management (UM), Complaints, Appeals & Grievances (CAG), and Pharmacy Management solutions, SmartProminence is designed to help health plans and pharmacy benefit managers more efficiently achieve operational
More news about: MHK
Nov 25, 2025, 10:01 ET Veterinary Reference Laboratory Market worth US$6.46 billion by 2030 with 6.3% CAGR | MarketsandMarkets™.
Animal Group (CAG); Water Quality Products (Water); Livestock, Poultry and Dairy (LPD); and Others.The Companion Animal Group is further segmented into CAG Diagnostics recurring, CAG Diagnostics capital-instruments, and Veterinary software, services and Diagnostic imaging systems. The CAG Diagnostics
More news about: MarketsandMarkets
Nov 20, 2025, 09:00 ET ReviR Therapeutics Receives $4.6 Million CIRM Grant to Advance Huntington's Disease Treatment and Announces Key Development Milestone
Huntington's disease is a neurodegenerative disorder caused by an abnormal expansion of CAG trinucleotide repeats in the huntingtin (HTT) gene. Individuals with HD have more than 36 CAG repeats in the HTT gene, resulting in the production of mutant huntingtin protein, which leads to the
More news about: ReviR Therapeutics
Nov 19, 2025, 07:30 ET Conagra Brands to Release Fiscal 2026 Second Quarter Earnings on December 19, 2025
CHICAGO, Nov. 19, 2025 /PRNewswire/ -- Conagra Brands, Inc. (NYSE: CAG) will release its fiscal 2026 second quarter results on Friday, December 19, 2025. A press release and supplemental materials, including pre-recorded
More news about: Conagra Brands, Inc.
Nov 13, 2025, 07:30 ET Conagra Brands Honors Employee Innovation with Its Sustainable Development Awards
CHICAGO, Nov. 13, 2025 /PRNewswire/ -- Conagra Brands (NYSE: CAG) announced the winners of its annual Sustainable Development Awards, honoring employees for their exceptional contributions that encourage sustainable
More news about: Conagra Brands, Inc.
Nov 04, 2025, 07:30 ET Conagra Brands to Participate in the J.P. Morgan U.S. Opportunities Forum
CHICAGO, Nov. 4, 2025 /PRNewswire/ -- Conagra Brands, Inc. (NYSE: CAG) will attend the J.P. Morgan U.S. Opportunities Forum on Wednesday, November 12.
More news about: Conagra Brands, Inc.